FDA — authorised 1 February 2013
- Application: NDA203284
- Marketing authorisation holder: HORIZON THERAP US
- Status: supplemented
FDA authorised Ravicti on 1 February 2013
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 1 February 2013; FDA has authorised it.
HORIZON THERAP US holds the US marketing authorisation.